Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, Maria Tariq, Price, Allyson, Ferrajoli, Alessandra, Borthakur, Gautam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515291/
https://www.ncbi.nlm.nih.gov/pubmed/34692401
http://dx.doi.org/10.1016/j.lrr.2021.100266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515291/
https://www.ncbi.nlm.nih.gov/pubmed/34692401
http://dx.doi.org/10.1016/j.lrr.2021.100266

Ejemplares similares